The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury

Abstract

Animal studies have consistently demonstrated the ability of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors to limit the damage induced by ischemia-reperfusion (IR) in the cardiac, cerebral and mesenteric circulation through a mechanism dependent on the upregulation of cyclooxygenase-2 (COX-2). Our group performed studies aimed at investigating the mechanism of HMG-CoA reductase inhibitor-mediated endothelial protection from IR injury, in particular the role of COX-2, in a human in vivo model of IR-induced endothelial dysfunction. We demonstrated that HMG-CoA reductase inhibition protects against IR-induced endothelial damage, an effect that was lost upon COX-2 inhibition. These observations may suggest a mechanistic explanation for the cardioprotection observed in clinical settings such as percutaneous coronary interventions and coronary artery bypass surgery and may also propose a mechanistic hypothesis for the reported cardiotoxic effects of cyclooxygenase-2 inhibitors observed in clinical studies. These studies are summarized and discussed in the present paper.